Pancreatic Cancer Stage IV Clinical Trial
Official title:
Phase I Study of Combination With TBI-1401(HF10), a Replication-competent HSV-1 Oncolytic Virus, and Chemotherapy in Patients With Stage III or IV Unresectable Pancreatic Cancer.
The purpose of this study is to determine the recommended dose of TBI-1401(HF10) treatment in combination with chemotherapy (Gemcitabine + Nab-paclitaxel or TS-1) in patients with stage III or IV unresectable pancreatic cancer.
A Phase I, open-label, multi-center study to determine the recommended dose of TBI-1401(HF10) treatment in combination with chemotherapy (Gemcitabine + Nab-paclitaxel or TS-1) in patients with stage III or IV unresectable pancreatic cancer. Patients with stage IV must failed a gemcitabine based first-line chemotherapy. Patients with stage III will receive the repeated intratumoral injection of TBI-1401(HF10) at recommended dose at 2-week intervals in combination with intravenous infusion of 1000 mg/m^2 Gemcitabine and 125 mg/m^2 Nab-paclitaxel at weekly for 3 weeks followed by 1 week rest. Patients with stage IV will receive the repeated intratumoral injection of TBI-1401(HF10) at recommended dose at 2-week intervals in combination with oral of 40 - 60 mg TS-1 at twice daily for 4 weeks followed by 2 weeks rest. Patients will receive the combination therapy of TBI-1401(HF10) + chemo for up to 1 year if eligible for treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT03697564 -
Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).
|
Phase 2 | |
| Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06017284 -
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
|
Phase 3 | |
| Recruiting |
NCT04674956 -
A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
|
Phase 3 | |
| Completed |
NCT03412799 -
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT04181645 -
SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
|
N/A | |
| Withdrawn |
NCT04852367 -
PanDox: Targeted Doxorubicin in Pancreatic Tumours
|
Phase 1 | |
| Recruiting |
NCT04150042 -
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
|
Phase 1 | |
| Recruiting |
NCT04628806 -
Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells
|
||
| Recruiting |
NCT02981641 -
IORT Versus CCRT for Pancreatic Cancer
|
N/A | |
| Completed |
NCT04953962 -
Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT05254171 -
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03236883 -
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT04406831 -
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
|
||
| No longer available |
NCT04137822 -
Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer
|